Charles River Laboratories (CRL)
Return on equity (ROE)
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Net income | US$ in thousands | 474,624 | 486,226 | 390,982 | 364,304 | 252,019 |
| Total stockholders’ equity | US$ in thousands | 3,596,880 | 2,976,290 | 2,534,820 | 2,114,600 | 1,634,580 |
| ROE | 13.20% | 16.34% | 15.42% | 17.23% | 15.42% |
December 31, 2023 calculation
ROE = Net income ÷ Total stockholders’ equity
= $474,624K ÷ $3,596,880K
= 13.20%
Charles River Laboratories' return on equity (ROE) has shown variability over the past five years, ranging from 13.20% in 2023 to 17.23% in 2020. The company's ROE peaked in 2020 before experiencing a decline in subsequent years. Despite the fluctuations, Charles River Laboratories' ROE has generally been above 15% since 2019, indicating that the company has been effectively generating earnings from shareholder equity. Further analysis of the factors influencing these changes in ROE, such as changes in profitability, asset utilization, and leverage, would provide a deeper understanding of the company's financial performance.
Peer comparison
Dec 31, 2023